import { EducationalContent } from '../../types';

export const cabg: EducationalContent = {
  id: 'cabg',
  type: 'concept',
  name: 'Coronary Artery Bypass Grafting',
  nameEs: 'Cirugia de Bypass Coronario',
  levels: {
    1: {
      level: 1,
      summary: 'Coronary artery bypass grafting (CABG) is an open-heart surgery that creates new pathways for blood to flow around blocked coronary arteries, restoring blood supply to the heart muscle.',
      explanation: 'Coronary artery bypass grafting, commonly called CABG (pronounced "cabbage"), is a surgical procedure used to treat severe coronary artery disease. Coronary artery disease occurs when the blood vessels that supply oxygen-rich blood to the heart muscle become narrowed or blocked by fatty deposits called plaque. When these blockages become severe, they can reduce blood flow to the heart, causing chest pain (angina) and increasing the risk of a heart attack.\n\nDuring CABG surgery, a surgeon takes a healthy blood vessel from another part of the body and uses it to create a detour or bypass around the blocked portion of the coronary artery. This new pathway allows blood to flow freely to the heart muscle, bypassing the blocked area. The blood vessels used for bypasses are called grafts.\n\nThe most commonly used grafts come from three sources. The internal mammary artery (also called internal thoracic artery) runs along the inside of the chest wall and can be redirected to connect to a coronary artery beyond the blockage. Saphenous veins are long veins taken from the leg. The radial artery from the forearm is also sometimes used. Surgeons may use a combination of these grafts depending on how many blockages need to be bypassed.\n\nThe number of bypasses needed depends on the number and location of blockages. Patients may hear their surgery described as single, double, triple, or quadruple bypass, referring to the number of coronary arteries that receive bypass grafts.\n\nCABG is typically performed through a large incision in the chest (median sternotomy), and most procedures use a heart-lung bypass machine that takes over the work of the heart and lungs during surgery so the surgeon can operate on a still heart. The surgery typically takes 3-6 hours, and recovery in the hospital is usually 5-7 days. Full recovery at home takes 6-12 weeks.\n\nCABG is one of the most commonly performed major surgeries in the world and has been proven to relieve angina symptoms, improve quality of life, and extend life in patients with severe coronary artery disease, particularly those with blockages in multiple coronary arteries or the left main coronary artery.',
      keyTerms: [
        { term: 'CABG', definition: 'Coronary artery bypass grafting; an open-heart surgery that creates new blood flow pathways around blocked coronary arteries' },
        { term: 'Graft', definition: 'A healthy blood vessel taken from another part of the body and used to bypass a blocked coronary artery' },
        { term: 'Internal mammary artery', definition: 'An artery on the inside of the chest wall that is commonly used as a bypass graft due to its excellent long-term patency' },
        { term: 'Heart-lung bypass machine', definition: 'A machine that temporarily takes over the pumping and oxygenating functions of the heart and lungs during open-heart surgery' },
        { term: 'Median sternotomy', definition: 'A surgical incision through the center of the breastbone (sternum) to access the heart for bypass surgery' }
      ],
      clinicalNotes: 'CABG is typically recommended for patients with significant left main coronary artery disease, three-vessel coronary artery disease (especially with reduced heart function), or complex multi-vessel disease not amenable to stenting. Patients should be counseled about the expected recovery timeline: sternal precautions (no lifting greater than 5-10 lbs, no driving) for 6-8 weeks, cardiac rehabilitation starting 2-4 weeks after discharge, and gradual return to full activity by 3 months.'
    },
    2: {
      level: 2,
      summary: 'CABG surgery uses arterial and venous conduits to bypass obstructive coronary lesions, with indications guided by coronary anatomy, ventricular function, and clinical presentation, utilizing on-pump or off-pump techniques.',
      explanation: 'Coronary artery bypass grafting is the most extensively studied cardiac surgical procedure, with over 50 years of accumulated evidence supporting its role in treating obstructive coronary artery disease. The procedure aims to restore myocardial perfusion, relieve ischemic symptoms, and improve survival in appropriately selected patients.\n\nGraft conduit selection significantly impacts long-term outcomes. The left internal mammary artery (LIMA, also called left internal thoracic artery or LITA) grafted to the left anterior descending artery (LAD) is the cornerstone of CABG surgery. The LIMA-to-LAD graft has a 10-year patency rate exceeding 90%, far superior to saphenous vein grafts (approximately 60% at 10 years). This remarkable patency is attributed to the intrinsic properties of the IMA: a single layer of internal elastic lamina that resists atherosclerosis, production of nitric oxide and prostacyclin that inhibit thrombosis, and size-matching with coronary arteries. The right internal mammary artery (RIMA) has similar properties and is increasingly used as a second arterial graft.\n\nSaphenous vein grafts (SVG) from the greater saphenous vein remain the most commonly used conduits for non-LAD targets. SVGs are subject to three phases of failure: early thrombosis (within 30 days, 3-12% of grafts), intimal hyperplasia (1 month to 1 year, contributing to progressive stenosis), and accelerated atherosclerosis (beyond 1 year). Approximately 40% of SVGs are occluded by 10 years. The radial artery, when used as a free graft, has intermediate patency between the IMA and SVG, with 5-year patency of approximately 85%. The radial artery is susceptible to vasospasm and requires calcium channel blocker therapy postoperatively.\n\nConventional CABG is performed on cardiopulmonary bypass (CPB, the heart-lung machine). The ascending aorta is cannulated for arterial return, the right atrium or venae cavae for venous drainage, and the heart is arrested using cold cardioplegia solution (high-potassium solution that stops the heart in diastole) delivered through the aortic root or coronary sinus. This provides a still, bloodless operative field.\n\nOff-pump coronary artery bypass (OPCAB) is performed on the beating heart without cardiopulmonary bypass, using mechanical stabilization devices (Octopus or Starfish) to immobilize the target area while the anastomoses are constructed. OPCAB avoids the systemic inflammatory response, hemodilution, and potential neurologic complications associated with CPB. However, large randomized trials (CORONARY, ROOBY) have shown mixed results, with some suggesting lower graft patency rates with OPCAB, particularly among less experienced surgeons.\n\nCurrent indications for CABG based on the 2021 ACC/AHA coronary revascularization guidelines include: left main coronary artery disease with greater than 50% stenosis (Class I), three-vessel disease (Class I, especially with depressed left ventricular function), two-vessel disease with proximal LAD involvement and reduced LVEF (Class I), and multivessel disease in diabetic patients (Class I, based on the FREEDOM trial). The SYNTAX score, which quantifies the complexity of coronary anatomy based on the number, location, and morphology of lesions, helps guide the choice between CABG and PCI, with higher SYNTAX scores (greater than 22) favoring CABG.',
      keyTerms: [
        { term: 'LIMA-to-LAD graft', definition: 'The gold standard bypass graft connecting the left internal mammary artery to the left anterior descending coronary artery, with greater than 90% patency at 10 years' },
        { term: 'Cardiopulmonary bypass (CPB)', definition: 'A technique using a heart-lung machine to maintain circulation and oxygenation while the heart is stopped during surgery' },
        { term: 'Cardioplegia', definition: 'A high-potassium solution delivered to the heart to induce cardiac arrest and provide myocardial protection during surgery' },
        { term: 'Off-pump CABG (OPCAB)', definition: 'A technique performing bypass surgery on the beating heart without cardiopulmonary bypass, using mechanical stabilizers to immobilize the target area' },
        { term: 'SYNTAX score', definition: 'An angiographic scoring system that quantifies coronary disease complexity based on lesion characteristics, used to guide the choice between CABG and PCI' },
        { term: 'Saphenous vein graft', definition: 'A conduit harvested from the leg vein for coronary bypass; subject to progressive failure with approximately 40% occlusion at 10 years' }
      ],
      clinicalNotes: 'The LIMA-to-LAD graft should be used in virtually all CABG operations unless contraindicated (subclavian stenosis, prior chest radiation damaging the IMA, emergency situations). Preoperative evaluation should include assessment of conduit availability (prior vein harvesting, varicose veins, Allen test for radial artery), carotid duplex ultrasound (for patients over 65 or with cerebrovascular symptoms), and pulmonary function testing if clinically indicated. Operative mortality for elective isolated CABG is approximately 1-2% and can be estimated preoperatively using the STS risk calculator.'
    },
    3: {
      level: 3,
      summary: 'Advanced CABG management encompasses total arterial revascularization strategies, minimally invasive approaches, intraoperative graft assessment, management of complex clinical scenarios including redo surgery and concomitant procedures, and evidence-based postoperative care protocols.',
      explanation: 'Advanced CABG practice integrates evolving surgical techniques, evidence-based conduit selection strategies, and comprehensive perioperative management to optimize outcomes in both standard and complex clinical scenarios.\n\nTotal arterial revascularization (TAR) aims to use exclusively arterial conduits for all bypass grafts, avoiding the inferior long-term patency of saphenous vein grafts. The bilateral internal mammary artery (BIMA) strategy uses both LIMA and RIMA, with the RIMA grafted as an in-situ graft to the right coronary territory or as a free graft to the circumflex territory, or routed through the transverse sinus (retro-aortic RIMA) to reach left-sided targets. The ART trial at 10-year follow-up showed a survival advantage for BIMA compared to single IMA grafting. However, BIMA use increases the risk of sternal wound complications, particularly in diabetic patients, obese patients, and those on chronic steroids. Skeletonized IMA harvesting (dissecting the artery from surrounding tissue) preserves collateral blood supply to the sternum, reducing wound complications.\n\nComposite and sequential grafting configurations maximize the number of targets revascularized with limited conduit length. A Y-graft (or T-graft) configuration anastomoses a free conduit (RIMA or radial artery) to the side of the in-situ LIMA, creating a branching conduit system. Sequential grafting involves multiple side-to-side anastomoses along the length of a single graft before a final end-to-side anastomosis, allowing one graft to perfuse multiple coronary targets (diamond, side-to-side anastomoses).\n\nMinimally invasive direct coronary artery bypass (MIDCAB) uses a small left anterior thoracotomy to harvest the LIMA and anastomose it to the LAD without cardiopulmonary bypass. MIDCAB avoids sternotomy and is suitable for single-vessel LAD disease. Robotic-assisted CABG uses the da Vinci surgical system for endoscopic IMA harvesting and, in some centers, the coronary anastomosis through small port incisions. The hybrid approach combines minimally invasive surgical LIMA-to-LAD grafting with percutaneous coronary intervention of non-LAD lesions, offering the best of both approaches: the superior patency of the LIMA-to-LAD graft combined with the less invasive nature of PCI for other targets.\n\nIntraoperative graft assessment methods include transit-time flow measurement (TTFM), which uses an ultrasonic flow probe placed around completed grafts to measure flow volume, pulsatility index, and diastolic filling fraction. Abnormal TTFM parameters (flow less than 15 mL/min, pulsatility index greater than 5, diastolic filling fraction less than 50%) suggest technical problems requiring graft revision. Intraoperative fluorescence angiography (using indocyanine green dye and near-infrared imaging) provides direct visualization of graft patency and can identify anastomotic problems.\n\nRedo CABG presents increased surgical risk due to adhesions, patent grafts that must be protected, and potential for aortic injury during resternotomy. Preoperative CT angiography is essential to define the relationship of cardiac structures and patent grafts to the sternum. Peripheral cannulation (femoral artery and vein) may be established before sternotomy as a safety measure. Alternative approaches include thoracotomy for single-vessel redo procedures.\n\nConcomitant procedures performed during CABG include aortic valve replacement (AVR + CABG), mitral valve repair or replacement (MVR + CABG), left atrial appendage closure, surgical ablation of atrial fibrillation (maze procedure), and ventricular aneurysm repair (Dor procedure). Each additional procedure incrementally increases operative risk and must be weighed against the expected benefit.\n\nPostoperative management priorities include hemodynamic optimization (maintaining adequate perfusion while avoiding excessive afterload on new grafts), early extubation protocols (ideally within 6 hours), aggressive pulmonary toilet to prevent atelectasis and pneumonia, glycemic control (target glucose 140-180 mg/dL, with insulin infusion showing mortality benefit in the NICE-SUGAR-adjacent cardiovascular surgery literature), and initiation of secondary prevention medications (aspirin, statin, beta-blocker, ACE inhibitor). Cardiac rehabilitation beginning 2-4 weeks after discharge significantly improves functional capacity, quality of life, and reduces 5-year mortality by approximately 20%.',
      keyTerms: [
        { term: 'Total arterial revascularization', definition: 'A CABG strategy using exclusively arterial conduits (bilateral IMAs, radial arteries) for all bypass grafts, avoiding saphenous vein grafts to maximize long-term patency' },
        { term: 'Bilateral internal mammary artery (BIMA)', definition: 'Use of both left and right internal mammary arteries as bypass conduits; associated with improved long-term survival but increased sternal wound complication risk' },
        { term: 'Transit-time flow measurement', definition: 'An intraoperative ultrasonic technique measuring blood flow through completed bypass grafts to verify patency and detect technical anastomotic problems' },
        { term: 'MIDCAB', definition: 'Minimally invasive direct coronary artery bypass; a technique using a small thoracotomy without sternotomy for LIMA-to-LAD grafting' },
        { term: 'Hybrid revascularization', definition: 'A combined approach using surgical LIMA-to-LAD grafting with PCI of non-LAD lesions, leveraging the advantages of both surgical and percutaneous techniques' },
        { term: 'Skeletonized IMA harvesting', definition: 'Dissection of the internal mammary artery from its surrounding tissue and veins, preserving sternal blood supply and reducing wound complications compared to pedicled harvesting' }
      ],
      clinicalNotes: 'When planning BIMA grafting, carefully weigh the long-term patency benefit against sternal wound risk. Skeletonized harvesting should be the standard technique, particularly in diabetic patients. Consider BIMA avoidance in patients with BMI greater than 35, poorly controlled diabetes (HbA1c greater than 8%), chronic steroid use, or severe COPD. Transit-time flow measurement should be performed on all grafts; revision rates of 3-5% are expected and lead to improved outcomes. For redo CABG, preoperative CT with 3D reconstruction is mandatory to plan the safest sternal re-entry strategy.'
    },
    4: {
      level: 4,
      summary: 'Complex CABG scenarios include management of the calcified aorta (porcelain aorta), deep hypothermic circulatory arrest for aortic surgery with CABG, extracorporeal membrane oxygenation bridge to CABG, and optimization of conduit biology through pharmacologic and gene therapy approaches.',
      explanation: 'Expert-level CABG surgery addresses technically challenging scenarios, emerging biological therapies, and complex multidisciplinary cases that require specialized surgical expertise and team-based decision-making.\n\nThe severely calcified (porcelain) aorta poses significant risk during CABG because standard aortic cannulation, cross-clamping, and proximal anastomosis sites risk atheroembolism and stroke. Management strategies include: (1) epiaortic ultrasound to identify disease-free areas for cannulation and anastomosis; (2) off-pump surgery with all-arterial in-situ grafts avoiding aortic manipulation (anaortic or no-touch technique); (3) single aortic cross-clamp technique (all proximal anastomoses constructed during a single cross-clamp period); (4) proximal anastomotic devices (Heartstring) that allow proximal vein graft anastomosis without side-biting clamps; and (5) alternative cannulation sites (axillary artery, femoral artery) when the ascending aorta is prohibitively diseased.\n\nCABG in acute myocardial infarction with cardiogenic shock requires emergent or urgent surgery with mechanical circulatory support. The IABP-SHOCK II trial showed no benefit of intra-aortic balloon pump in cardiogenic shock, shifting practice toward Impella or extracorporeal membrane oxygenation (ECMO) as bridge-to-surgery strategies. VA-ECMO provides biventricular support, allowing hemodynamic stabilization and end-organ recovery before definitive surgical revascularization. The timing of CABG after MI is debated: emergent CABG within 6 hours of symptom onset for failed PCI or left main occlusion, versus delayed CABG (3-7 days) for stable patients to allow myocardial recovery and reduce operative inflammation.\n\nConcomitant CABG with aortic surgery includes combined CABG with ascending aortic replacement, aortic root replacement (Bentall procedure), and aortic arch repair. Arch surgery requires hypothermic circulatory arrest with cerebral perfusion strategies: deep hypothermic circulatory arrest (DHCA, 18-20 degrees Celsius) provides a limited safe period of approximately 30-40 minutes, while antegrade selective cerebral perfusion (ASCP) via the axillary artery or direct ostial cannulation extends the safe arrest time significantly. Retrograde cerebral perfusion through the SVC is used as an adjunct in some centers.\n\nVein graft biology and failure prevention represent active research areas. External stenting of saphenous vein grafts using bioabsorbable mesh constrains the vein to arterial dimensions, preventing dilation, reducing wall shear stress alterations, and potentially reducing intimal hyperplasia. The VEST trial showed improved vein graft uniformity with external stenting, and long-term patency data are maturing. Gene therapy approaches include adenoviral-mediated delivery of tissue factor pathway inhibitor (TFPI), endothelial nitric oxide synthase (eNOS), or decoy oligodeoxynucleotides targeting E2F transcription factor to vein grafts at the time of surgery, aiming to reduce neointimal hyperplasia and atherosclerosis.\n\nEndoscopic vein harvesting (EVH) has become the standard technique for saphenous vein procurement, reducing leg wound complications (infection, hematoma, pain) compared to open harvesting. However, early concerns about reduced graft patency with EVH (potentially from endothelial damage during harvesting) have been addressed by refinements in technique, and contemporary data show comparable patency when performed by experienced operators.\n\nMyocardial protection strategies during on-pump CABG continue to evolve. Del Nido cardioplegia, originally developed for pediatric cardiac surgery, uses a single-dose delivery strategy that provides 60-90 minutes of myocardial protection, simplifying the operative workflow. Microplegia uses miniaturized perfusion circuits to deliver warm blood cardioplegia with minimal hemodilution. Custodiol (HTK solution) provides extended single-dose protection useful for complex, lengthy procedures.\n\nThe STS National Database provides risk-adjusted outcomes benchmarking for CABG programs. Key quality metrics include operative mortality, stroke rate, renal failure requiring dialysis, deep sternal wound infection, and prolonged ventilation. The STS composite quality score integrates multiple outcomes and process measures, and is publicly reported, driving continuous quality improvement in cardiac surgical programs.',
      keyTerms: [
        { term: 'Anaortic (no-touch) technique', definition: 'A CABG approach that avoids all manipulation of the ascending aorta to eliminate atheroembolism risk, using in-situ arterial grafts and off-pump surgery' },
        { term: 'Epiaortic ultrasound', definition: 'Intraoperative ultrasound scanning of the ascending aorta to identify atherosclerotic disease and guide safe cannulation and anastomotic site selection' },
        { term: 'External vein graft stenting', definition: 'Application of a bioabsorbable mesh around saphenous vein grafts to constrain dilation and potentially reduce neointimal hyperplasia and late graft failure' },
        { term: 'Del Nido cardioplegia', definition: 'A single-dose crystalloid-based cardioplegia solution providing extended myocardial protection, originally developed for pediatric surgery and increasingly adopted for adult CABG' },
        { term: 'Antegrade selective cerebral perfusion', definition: 'A neuroprotection strategy during aortic arch surgery delivering oxygenated blood to the brain via axillary artery or direct cannulation while the body is in circulatory arrest' },
        { term: 'STS risk calculator', definition: 'A validated predictive model using the Society of Thoracic Surgeons database to estimate operative mortality and morbidity risk for individual CABG patients' }
      ],
      clinicalNotes: 'Epiaortic ultrasound should be performed in all CABG patients, as palpation misses significant aortic disease in 20-40% of cases. The porcelain aorta mandates modification of the surgical plan; options should be discussed in a Heart Team conference. For patients with cardiogenic shock requiring CABG, establish mechanical circulatory support (Impella or ECMO) before surgical intervention to stabilize hemodynamics and allow end-organ recovery. The STS Predicted Risk of Mortality should be calculated and discussed with the patient during preoperative consent, as it provides the most accurate risk estimate available.'
    },
    5: {
      level: 5,
      summary: 'Frontier CABG research encompasses robotic and totally endoscopic surgery, coronary artery tissue engineering, stem cell-enhanced conduits, artificial intelligence for surgical planning and outcomes prediction, and the evolving paradigm of personalized revascularization strategy.',
      explanation: 'The frontier of coronary bypass surgery integrates robotic technology, regenerative medicine, computational optimization, and precision medicine approaches that aim to improve outcomes while reducing surgical invasiveness.\n\nTotally endoscopic coronary artery bypass (TECAB) using the da Vinci robotic system represents the ultimate minimally invasive approach, performing all aspects of CABG (IMA harvesting, anastomosis construction) through small port incisions without sternotomy or thoracotomy. TECAB can be performed on cardiopulmonary bypass (arrested TECAB) or on the beating heart. The learning curve is steep (50-100 cases for proficiency), and current adoption is limited to high-volume centers. Single-vessel TECAB for LIMA-to-LAD grafting has demonstrated comparable patency to open CABG in experienced hands, with dramatically reduced recovery time and improved cosmesis.\n\nTissue-engineered coronary grafts represent a paradigm shift from autologous conduit harvesting. Approaches include: (1) decellularized vascular scaffolds from human or porcine donors, repopulated with autologous endothelial and smooth muscle cells; (2) completely synthetic biodegradable polymer scaffolds (electrospun polycaprolactone, polyglycolic acid) that serve as temporary templates for neovessel formation; (3) self-assembled tissue-engineered vascular grafts grown from patient-derived cells in bioreactors without synthetic scaffolds. The Humacyte human acellular vessel (HAV), derived from cultured human vascular smooth muscle cells on a degradable scaffold followed by decellularization, has completed Phase II trials for peripheral vascular access and is being investigated for coronary applications.\n\nStem cell therapy combined with CABG aims to regenerate myocardium in areas of chronic ischemia or infarction. Direct injection of autologous bone marrow mononuclear cells, mesenchymal stem cells, or cardiac progenitor cells into the peri-infarct zone during CABG has been investigated in multiple trials. The PROMETHEUS trial demonstrated improved myocardial perfusion and function in CABG patients receiving mesenchymal stem cell injections into non-bypassed territories. However, the mechanism of benefit likely involves paracrine signaling and angiogenesis rather than true cardiomyocyte regeneration, and optimal cell type, dosing, and delivery method remain under investigation.\n\nArtificial intelligence applications in CABG include: (1) preoperative planning using machine learning algorithms to predict optimal conduit selection based on patient characteristics, coronary anatomy, and conduit quality assessment (CT angiography of IMA and radial artery, venous mapping); (2) intraoperative guidance using augmented reality displays that overlay coronary anatomy from preoperative imaging onto the surgical field; (3) surgical outcome prediction using neural networks trained on large national databases (STS, ANZSCTS) that outperform traditional logistic regression models; and (4) quality improvement through automated surgical video analysis identifying technical factors associated with graft failure.\n\nThe evolving paradigm of personalized revascularization integrates coronary anatomy (SYNTAX score), physiologic assessment (FFR/iFR), patient factors (diabetes, renal function, frailty), myocardial viability (CMR or PET), and long-term prognostic models into a comprehensive decision framework that moves beyond the binary CABG-versus-PCI choice. The ISCHEMIA trial demonstrated that in patients with stable ischemic heart disease and moderate-to-severe ischemia, an initial invasive strategy did not reduce events compared to optimal medical therapy. This has shifted the conversation toward reserving revascularization for patients most likely to derive survival benefit (left main, severe three-vessel disease, reduced LVEF) or symptom benefit (refractory angina despite optimal medical therapy).\n\nPostoperative graft surveillance using non-invasive coronary CT angiography at 1 and 5 years is being investigated as a strategy to detect graft failure before clinical events occur, enabling prophylactic re-intervention. Machine learning analysis of longitudinal post-CABG data may identify patient phenotypes at highest risk for graft failure, enabling targeted surveillance and secondary prevention intensification.\n\nThe convergence of robotic surgery, tissue engineering, AI-guided planning, and precision medicine is creating a future where CABG is not a standardized operation but a personalized therapeutic strategy tailored to individual coronary anatomy, conduit biology, myocardial substrate, and patient preferences.',
      keyTerms: [
        { term: 'Totally endoscopic CABG (TECAB)', definition: 'Robotic-assisted bypass surgery performed entirely through small port incisions without sternotomy, using the da Vinci surgical system for IMA harvesting and coronary anastomosis' },
        { term: 'Tissue-engineered coronary grafts', definition: 'Laboratory-grown vascular conduits using decellularized scaffolds, synthetic polymers, or self-assembled cell sheets as alternatives to harvested autologous vessels' },
        { term: 'Stem cell-enhanced CABG', definition: 'Injection of autologous stem cells into ischemic myocardium during CABG to promote angiogenesis and potentially regenerate damaged heart tissue' },
        { term: 'Augmented reality surgical guidance', definition: 'Overlay of preoperative imaging data onto the real-time surgical field to enhance anatomic visualization and guide precise anastomosis placement' },
        { term: 'Personalized revascularization', definition: 'An evolving paradigm integrating anatomic, physiologic, viability, and patient-specific data to individualize the choice between CABG, PCI, and medical therapy' },
        { term: 'Human acellular vessel', definition: 'A bioengineered vascular graft derived from cultured human cells on a degradable scaffold, subsequently decellularized to create an off-the-shelf conduit that does not require immunosuppression' }
      ],
      clinicalNotes: 'TECAB should only be performed in high-volume centers with robotic cardiac surgical expertise. The learning curve is substantial, and complication rates are higher during the initial experience. Tissue-engineered grafts and stem cell therapy remain investigational and should only be offered within clinical trials. The ISCHEMIA trial results should be discussed with patients as part of shared decision-making for elective revascularization. Post-CABG follow-up should include lifelong secondary prevention optimization (statin, aspirin, blood pressure control, diabetes management, smoking cessation), as medical therapy failure is the most common cause of late cardiac events after CABG.'
    }
  },
  media: [],
  citations: [
    { id: 'cabg-c1', source: 'Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. Circulation. 2022;145(3):e18-e114.', url: 'https://doi.org/10.1161/CIR.0000000000001038' },
    { id: 'cabg-c2', source: 'Taggart DP, Benedetto U, Gerry S, et al. Bilateral versus Single Internal-Thoracic-Artery Grafts at 10 Years (ART Trial). N Engl J Med. 2019;380(5):437-446.', url: 'https://doi.org/10.1056/NEJMoa1808783' },
    { id: 'cabg-c3', source: 'Maron DJ, Hochman JS, Reynolds HR, et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease (ISCHEMIA Trial). N Engl J Med. 2020;382(15):1395-1407.', url: 'https://doi.org/10.1056/NEJMoa1915922' }
  ],
  crossReferences: [
    { contentId: 'pci', relationship: 'related', description: 'PCI is the principal alternative to CABG for coronary revascularization, with selection guided by anatomy and patient factors' },
    { contentId: 'cardiaccath', relationship: 'related', description: 'Cardiac catheterization with coronary angiography defines the coronary anatomy guiding CABG surgical planning' },
    { contentId: 'stresstest', relationship: 'related', description: 'Stress testing identifies ischemia that may lead to coronary angiography and subsequent CABG recommendation' }
  ],
  tags: {
    defined: ['cardiac-surgery', 'CABG', 'coronary-revascularization', 'bypass-grafting', 'coronary-artery-disease', 'surgical-intervention'],
    generated: ['LIMA-LAD', 'arterial-conduit', 'off-pump', 'SYNTAX-score', 'graft-patency', 'total-arterial']
  },
  createdAt: '2025-01-25',
  updatedAt: '2025-01-25',
  version: 2,
  status: 'published'
};
